These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23560129)

  • 21. [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
    Wollenberg A; Staehler M; Eames T
    Hautarzt; 2010 Aug; 61(8):662-7. PubMed ID: 20631979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib.
    Iacovelli R; Mancini ML; Risi E; Palazzo A; Cortesi E
    Int J Dermatol; 2012 Feb; 51(2):221-2. PubMed ID: 22250635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent scrotal hemangiomas during treatment with sunitinib.
    Tonini G; Intagliata S; Cagli B; Segreto F; Perrone G; Onetti Muda A; Santini D; Persichetti P
    J Clin Oncol; 2010 Dec; 28(35):e737-8. PubMed ID: 20823408
    [No Abstract]   [Full Text] [Related]  

  • 24. Sunitinib adverse event: oral bullous and lichenoid mucositis.
    Mignogna MD; Fortuna G; Leuci S; Pollio A; Ruoppo E
    Ann Pharmacother; 2009 Mar; 43(3):546-7. PubMed ID: 19240256
    [No Abstract]   [Full Text] [Related]  

  • 25. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
    Kalantari HR
    Br J Cancer; 2009 Oct; 101(7):1222-3; author reply 1224. PubMed ID: 19755985
    [No Abstract]   [Full Text] [Related]  

  • 26. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
    Chu D; Lacouture ME; Weiner E; Wu S
    Clin Genitourin Cancer; 2009 Jan; 7(1):11-9. PubMed ID: 19213662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurosensory retinal detachment due to sunitinib treatment.
    Wegner A; Khoramnia R
    Eye (Lond); 2011 Nov; 25(11):1517-8. PubMed ID: 21852804
    [No Abstract]   [Full Text] [Related]  

  • 28. [Leg ulcerations and sunitinib].
    Guyot-Caquelin P; Granel-Brocard F; Cuny JF; Trechot P; Spaeth D; Marchal A; Barbaud A; Schmutz JL
    Ann Dermatol Venereol; 2010 Oct; 137(10):626-9. PubMed ID: 20932442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eccrine squamous syringometaplasia associated with vemurafenib therapy.
    Story SG; Beschloss JK; Dolan CK; Thomas BC
    J Am Acad Dermatol; 2012 Nov; 67(5):e208-10. PubMed ID: 23062917
    [No Abstract]   [Full Text] [Related]  

  • 30. Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy?
    Soria JC; Deutsch E
    Ann Oncol; 2011 Jun; 22(6):1247-1249. PubMed ID: 21382869
    [No Abstract]   [Full Text] [Related]  

  • 31. Risks associated with sunitinib use and monitoring to improve patient outcomes.
    Choi BS
    Korean J Intern Med; 2014 Jan; 29(1):23-6. PubMed ID: 24574829
    [No Abstract]   [Full Text] [Related]  

  • 32. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
    Porta C; Paglino C; Imarisio I; Bonomi L
    Clin Exp Med; 2007 Dec; 7(4):127-34. PubMed ID: 18188524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sunitinib-induced thyrotoxicosis.
    Piñar D; Boix E; Meana JA; Herrero J
    J Endocrinol Invest; 2009 Dec; 32(11):941-2. PubMed ID: 19636224
    [No Abstract]   [Full Text] [Related]  

  • 34. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
    McLellan B; Kerr H
    Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myelosuppression by sunitinib is flt-3 genotype dependent.
    van Erp NP; Mathijssen RH; van der Veldt AA; Haanen JB; Reyners AK; Eechoute K; Boven E; Wessels JA; Guchelaar HJ; Gelderblom H
    Br J Cancer; 2010 Aug; 103(5):757-8. PubMed ID: 20683446
    [No Abstract]   [Full Text] [Related]  

  • 36. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.
    Kapiteijn E; Brand A; Kroep J; Gelderblom H
    Ann Oncol; 2007 Oct; 18(10):1745-7. PubMed ID: 17890216
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of hemodialyzed patient with sunitinib.
    Reckova M; Kakalejcik M; Beniak J
    Ann Oncol; 2009 Feb; 20(2):392-3. PubMed ID: 19136449
    [No Abstract]   [Full Text] [Related]  

  • 38. Lung toxicity in a patient treated with sunitinib.
    Boyle HJ; Chatté G; Rivoire M; Fléchon A
    Eur Respir J; 2012 Nov; 40(5):1300-3. PubMed ID: 23115316
    [No Abstract]   [Full Text] [Related]  

  • 39. Case of sunitinib-induced Stevens-Johnson syndrome.
    Lee JH; Lee JH; Lee JH; Kim SY; Kim GM
    J Dermatol; 2013 Sep; 40(9):753-4. PubMed ID: 23855706
    [No Abstract]   [Full Text] [Related]  

  • 40. Sporadic CNS hemangioblastomatosis, response to sunitinib and secondary polycythemia.
    Reyes-Botero G; Gállego Pérez-Larraya J; Sanson M
    J Neurooncol; 2012 Apr; 107(2):439-40. PubMed ID: 22076450
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.